Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment With Bruton's Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib

NCT04938141 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04938141
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04938141 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment With Bruton's Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
October 7, 2021
Completion date
September 26, 2024
Enrollment
23 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia